Session 2: Determining Potency of Immunologic Therapy

- If immune “drug” potency is defined as an immune outcome- what parameters should be used to define potency?
  - (ex vivo function or in vivo activity? What are we measuring against?)

- Is there one assay that should be performed on all studies to help define “potency” in vivo?
  - e.g. ELISPOT, polyfunctional T cells by flow cytometry
  - Quality vs. quantity

- What are key assays to measure product potency ex vivo?
  - e.g. for infused T cells, NK cells, DC vaccines